Plasminogen intravenous - ProMetic Life Sciences

Drug Profile

Plasminogen intravenous - ProMetic Life Sciences

Alternative Names: Ryplazym

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Antithrombotics; Beta-globulins
  • Mechanism of Action Plasmin modulators; Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type I plasminogen deficiency
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type I plasminogen deficiency
  • Preclinical Acute lung injury; Wounds

Most Recent Events

  • 11 Jul 2017 Prometic Life Sciences announces intention to complete regulatory filing to Health Canada for Type I plasminogen deficiency in Q4 2017
  • 11 Jul 2017 Prometic announces intention to submit MAA to EMA for Type I plasminogen deficiency
  • 11 Jul 2017 Interim adverse events, pharmacokinetics and efficacy data from a phase II/III trial in Type I plasminogen deficiency released by Prometic Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top